Nod-Like Receptors in the Pathogenesis of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Therapeutic Agents Targeting Nod-Like Receptors

Nod-Like Receptors in the Pathogenesis of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Therapeutic Agents Targeting Nod-Like Receptors Publisher Pubmed

Khanmohammadi S¹ ; Ramosmolina B² ; Kuchay MS³

Show Affiliations

1. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Science, Tehran, Iran
2. Obesity and Metabolism Laboratory, Biomedical Research Institute of Murcia (IMIB), Murcia, 30120, Spain
3. Medanta the Medicity Hospital, Divison of Endocrinology and Diabetes, Gurugram, 122001, Haryana, India

Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews Published:2023

Abstract

Background and aims: In metabolic (dysfunction)-associated fatty liver disease (MAFLD), activation of inflammatory processes marks the transition of simple steatosis to steatohepatitis, which can further evolve to advanced fibrosis or hepatocellular carcinoma. Under the stress of chronic overnutrition, the innate immune system orchestrates hepatic inflammation through pattern recognition receptors (PRRs). Cytosolic PRRs that include NOD-like receptors (NLRs) are crucial for inducing inflammatory processes in the liver. Methods: A literature search was performed with Medline (PubMed), Google Scholar and Scopus electronic databases till January 2023, using relevant keywords to extract studies describing the role of NLRs in the pathogenesis of MAFLD. Results: Several NLRs operate through the formation of inflammasomes, which are multimolecular complexes that generate pro-inflammatory cytokines and induce pyroptotic cell death. A multitude of pharmacological agents target NLRs and improve several aspects of MAFLD. In this review, we discuss the current concepts related to the role of NLRs in the pathogenesis of MAFLD and its complications. We also discuss the latest research on MAFLD therapeutics functioning through NLRs. Conclusions: NLRs play a significant role in the pathogenesis of MAFLD and its consequences, especially through generation of inflammasomes, such as NLRP3 inflammasomes. Lifestyle changes (exercise, coffee consumption) and therapeutic agents (GLP-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors, obeticholic acid) improve MAFLD and its complications partly through blockade of NLRP3 inflammasome activation. New studies are required to explore these inflammatory pathways fully for the treatment of MAFLD. © 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC)

Related Docs

1. Toll-Like Receptors and Metabolic (Dysfunction)-Associated Fatty Liver Disease, Pharmacological Research (2022)

2. Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms, Journal of Obesity and Metabolic Syndrome (2024)

3. Immune Landscape of Hepatocellular Carcinoma: From Dysregulation of the Immune Responses to the Potential Immunotherapies, Cell Biochemistry and Function (2024)

4. Sglt2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and Nafld, Endocrinology (United States) (2021)

5. Dietary Inflammatory Potential and Metabolic (Dysfunction)-Associated Steatotic Liver Disease and Its Complications: A Comprehensive Review, Clinical Nutrition ESPEN (2025)

Experts (# of related papers)

Nima Rezaei (2)

Style	Citing Format
MLA	Khanmohammadi S, Ramosmolina B, Kuchay MS. "Nod-Like Receptors in the Pathogenesis of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Therapeutic Agents Targeting Nod-Like Receptors." Diabetes and Metabolic Syndrome: Clinical Research and Reviews, vol. 17, no. 7, 2023, pp. -.
APA	Khanmohammadi S, Ramosmolina B, Kuchay MS (2023). Nod-Like Receptors in the Pathogenesis of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Therapeutic Agents Targeting Nod-Like Receptors. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 17(7), -.
Chicago	Khanmohammadi S, Ramosmolina B, Kuchay MS. "Nod-Like Receptors in the Pathogenesis of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Therapeutic Agents Targeting Nod-Like Receptors." Diabetes and Metabolic Syndrome: Clinical Research and Reviews 17, no. 7 (2023): -.
Harvard	Khanmohammadi S, Ramosmolina B, Kuchay MS (2023) 'Nod-Like Receptors in the Pathogenesis of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Therapeutic Agents Targeting Nod-Like Receptors', Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 17(7), pp. -.
Vancouver	Khanmohammadi S, Ramosmolina B, Kuchay MS. Nod-Like Receptors in the Pathogenesis of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Therapeutic Agents Targeting Nod-Like Receptors. Diabetes and Metabolic Syndrome: Clinical Research and Reviews. 2023;17(7):-.
BibTex	@article{ author = {Khanmohammadi S and Ramosmolina B and Kuchay MS}, title = {Nod-Like Receptors in the Pathogenesis of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Therapeutic Agents Targeting Nod-Like Receptors}, journal = {Diabetes and Metabolic Syndrome: Clinical Research and Reviews}, volume = {17}, number = {7}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Khanmohammadi S AU - Ramosmolina B AU - Kuchay MS TI - Nod-Like Receptors in the Pathogenesis of Metabolic (Dysfunction)-Associated Fatty Liver Disease: Therapeutic Agents Targeting Nod-Like Receptors JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews VL - 17 IS - 7 SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract